Confirm the identity first
TB-500 should not be treated as interchangeable with full-length thymosin beta-4. Analytical research identified a marketed TB-500 preparation as the short acetylated fragment Ac-LKKTETQ. That distinction matters when comparing product specifications and publications.
What did later experiments find?
A 2024 study examined that fragment and its metabolites in laboratory systems and rats. In a cell-based wound-healing experiment, a metabolite showed activity while the parent compound did not. A finding about the metabolite is not the same as a finding about TB-500 itself.
Do not transfer claims between molecules
Research on full-length thymosin beta-4, a fragment and a metabolite should be kept distinct. These findings do not establish that the sample TB-500 listing produces a recovery benefit in people.
What to check on the record
A finished specification needs to identify the exact material being offered. This mockup deliberately does not invent a sequence, molecular weight or real analytical result for its sample vial. The certificate demonstrates how a lot-specific record would be presented.
Read the sources
Educational information, not personal medical advice. Research findings do not validate this sample catalog or its demonstration certificates.